PARP Inhibitors Are a Mainstay in Metastatic Breast CancerMarch 8th 2021
Olaparib and talazoparib didn't show statistically significant improvements in overall survival compared with chemotherapy in certain patients with metastatic breast cancer. However, the results are unlikely to affect the drugs’ utility in practice, given that both agents continue to show favorable tolerability and disease control.
Personalized Approach May Boost AI AdherenceJanuary 6th 2021
Twice-weekly text message reminders did not improve adherence to aromatase inhibitors (AIs) for postmenopausal patients with early-stage breast cancer; therefore, increasing the odds of long-term adherence for this population will require more personalized approaches, explained Julie Gralow, MD.
ADC ARX788 Gets Fast Track Status for HER2+ Metastatic Breast CancerJanuary 6th 2021
The FDA has granted a fast track designation to the investigational antibody-drug conjugate (ADC) ARX788 for use as a monotherapy in the treatment of patients with advanced or metastatic HER2-positive breast cancer who have previously received 1 or more HER2-targeted regimens in the metastatic setting.
HER2-Positive Breast Cancer Biomarkers: The Search ContinuesJanuary 5th 2021
Patients with early-stage HER2-positive breast cancer should be treated with neoadjuvant therapy rather than surgery to determine how they will respond to ado-trastuzumab emtansine (T-DM1; Kadcyla)in the adjuvant setting, according to Ian E. Krop, MD, PhD, who added that although residual disease may serve as a potential predictive biomarker for response to this approach, the hunt for effective molecular biomarkers continues.
Chemoimmunotherapy Combos Push Forward in TNBC TreatmentDecember 27th 2020
Several novel chemoimmunotherapy combinations have risen to the forefront of treatment in triple-negative breast cancer (TNBC), according to Neelima Vidula, MD. However, what the optimal chemotherapy backbone is, which PD-L1 assay should be utilized, and whether this approach will play a role in the neoadjuvant setting are all questions that remain unanswered.
FDA Approves Margetuximab-cmkb Plus Chemo in Metastatic HER2+ Breast CancerDecember 17th 2020
The FDA has approved margetuximab-cmkb (Margenza) plus chemotherapy for use in adult patients with metastatic HER2-positive breast cancer who have previously received 2 or more anti-HER2 regimens, at least one of which was for metastatic disease.
Managing GI AEs in Metastatic Breast CancerDecember 15th 2020
Gastrointestinal (GI) adverse events (AEs) that occurred in patients with metastatic breast cancer who were treated with oral paclitaxel and encequidar can be managed by the use of 5- HT3 inhibitors and early intervention with loperamide, according to research presented at the 2020 San Antonio Breast Cancer Symposium.
Nurse Navigation in Safety Net Hospital Resulted in Less Frequent Care Refusal for Patients with Breast CancerDecember 14th 2020
A poster presented at the 2020 San Antonio Breast Cancer Symposium found a trend towards less frequent care refusal when a safety net hospital introduced nurse breast navigators.
Study Shows Need for Evidence-Based, Educational Material for Providers and Patients with Metastatic Breast CancerDecember 11th 2020
Recent research highlighted the need for reliable information to address the educational and psychosocial needs of patients with newly diagnosed metastatic breast cancer.
Asian Patients With HR+, HER2- Breast Cancer Have Higher Recurrence RiskNovember 23rd 2020
Patients from Asian countries with hormone receptor (HR)–positive, HER2-negative breast cancer may have a higher risk of disease recurrence than those from non-Asian countries, suggesting that this population may benefit from additional adjuvant treatment with abemaciclib (Verzenio).
FDA Approves Pembrolizumab Plus Chemo for TNBCNovember 14th 2020
The FDA granted an accelerated approval to pembrolizumab (Keytruda) plus chemotherapy for the treatment of patients with locally recurrent, unresectable or metastatic triple-negative breast cancer (TNBC) with PD-L1 expression is CPS ≥10, according to the agency.
Triple-Negative Breast Cancer Treatments Continue to EvolveNovember 4th 2020
Beyond single-agent chemotherapy, few effective treatment options are available for metastatic triple-negative breast cancer (TNBC), according to Candace Mainor, MD, but several approaches comprised of immunotherapy, antibody-drug conjugates (ADCs), and PARP inhibitors are shifting standards of care and eliciting impressive response rates in heavily pretreated patients.
FDA Recommends Black-Box Warning on Breast ImplantsSeptember 30th 2020
Makers of breast implants should supplement their labeling to include a boxed warning about health problems that can arise from the devices, along with a patient decision checklist that highlights those concerns, according to final guidance issued today by the Food and Drug Administration.